CorriXR Therapeutics
Operator of a gene editing company, intended to develop therapeutics and treat cancer using CRISPR technology, met with the FDA to discuss plans for a clinical trial. The company's platform technology...
Valuation
$0
Share Price
N/A
Total Raised
$25M
Last Round
N/A